Hengrui Pharmaceutical (01276): RSS0393 ointment approved for clinical trials

Zhitongcaijing · 09/04/2025 10:25

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company's subsidiary Ruishi Biomedical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for RSS0393 ointment, which will conduct clinical trials in the near future.

RSS0393 ointment is an ointment containing PDE4 small molecule inhibitors developed independently by the company. After application, it can inhibit PDE4 activity in various cells and relieve tissue damage and inflammation. For atopic dermatitis, similar drugs such as ARCUTIS's rofloxate cream (ZORYVE®), Pfizer's EUCRISA®, and Otsuka's difamist® ointment (MOIZERTO®) have been approved for marketing worldwide; claribolol ointment has been approved for marketing in China. According to the EvaluatePharma database, the total global sales volume of rofloxate cream and difamist ointment in 2024 was approximately US$254 million. Up to now, projects related to RSS0393 ointment have invested a total of about 28.5 million yuan in R&D.